Company News: AstraZeneca

Share this article:
The FDA approved Crestor for use in patients who are not currently suffering from heart disease but who may be considered at-risk based on age (50 and over for men, 60 and over for women), elevated CRP levels and at least one other risk factor, including smoking, hypertension, low HDL-C or family history of early heart disease. In observance of the PhRMA guiding principles on DTC, the brand will defer consumer advertising on the expanded label for awhile while reps detail doctors on it first. Messaging around the brand's unique indication for slowing the progression of atherosclerosis will continue to be a key part of the brand's overall message, said an AstraZeneca spoke.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.